CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
OPERATING ACTIVITIES:
Net loss	$ (140,775,000)	$ (42,314,000)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Stock-based compensation expense	68,383,000	29,698,000
Depreciation	14,351,000	13,578,000
Amortization of purchased intangibles and finance leases	10,799,000	3,108,000
Amortization of debt issuance costs	1,885,000	1,228,000
Accretion of debt discount on convertible senior notes	0	16,374,000
Allowance for credit losses	3,477,000	1,599,000
Gain on settlement of leases	0	(3,322,000)
Deferred income taxes	926,000	(1,408,000)
Changes in operating assets and liabilities:
Accounts receivable	(32,734,000)	(11,665,000)
Prepaid expenses and other current assets	(7,981,000)	(3,938,000)
Contract acquisition costs noncurrent	(4,758,000)	(3,557,000)
Other assets	(111,000)	597,000
Accounts payable	6,816,000	(6,548,000)
Accrued expenses and other current liabilities	3,941,000	20,527,000
Deferred revenue	13,049,000	20,126,000
Operating lease liabilities	(1,721,000)	(3,312,000)
Other liabilities	86,000	(157,000)
Net cash (used in) provided by operating activities	(64,367,000)	30,614,000
INVESTING ACTIVITIES:
Purchases of property and equipment, including capitalized software	(25,197,000)	(23,172,000)
Investment in joint venture	(3,651,000)	0
Payments for acquisition, net of cash acquired	(3,458,000)	0
Payments for intangible assets	(1,129,000)	(1,375,000)
Net cash used in investing activities	(33,435,000)	(24,547,000)
FINANCING ACTIVITIES:
Principal payments for financing leases	(1,849,000)	(1,728,000)
Proceeds from issuance of common stock in connection with the exercise of options and ESPP	895,000	9,001,000
Payments on conversion of convertible senior notes	0	(2,000)
Net cash (used in) provided by financing activities	(954,000)	7,271,000
Effect of foreign exchange rate changes on cash and cash equivalents	1,578,000	(1,882,000)
Net (decrease) increase in cash, cash equivalents, and restricted cash	(97,178,000)	11,456,000
Cash, cash equivalents, and restricted cash - beginning of year	523,532,000	654,152,000
Cash, cash equivalents, and restricted cash - end of period	426,354,000	665,608,000
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]
Cash and cash equivalents	425,944,000	664,334,000
Restricted cash in prepaid expenses and other current assets	410,000	1,274,000
Total cash, cash equivalents, and restricted cash	426,354,000	665,608,000
Supplemental disclosure of other cash flow information:
Cash paid for income taxes	2,237,000	686,000
Cash paid for interest	985,000	1,041,000
Supplemental disclosure of non-cash investing and financing activities:
Increase in convertible senior notes, net upon adoption of ASU 2020-06 (Note 1)	159,407,000	0
Purchase of property and equipment recorded in accounts payable	837,000	640,000
Issuance of shares of common stock to settle cash awards	17,298,000	33,503,000
Right of use assets obtained in exchange for operating lease liabilities	$ 2,417,000	0
WildHealth
Supplemental disclosure of non-cash investing and financing activities:
Issuance of 779,946 shares of common stock in connection with the WildHealth transaction in February 2022 (shares)	776,825
Issuance of 776,825 shares of common stock in connection with the WildHealth transaction in February 2022	$ 17,675,000	0
Issuance of 776,825 shares of common stock in connection with the WildHealth transaction in February 2022	$ 17,675,000	$ 0
Issuance of 779,946 shares of common stock in connection with the WildHealth transaction in February 2022 (shares)	776,825